Drug profile · INN
icatibant acetate
ICATIBANT ACETATE
icatibant acetate (ICATIBANT ACETATE) is a bradykinin b2 receptor antagonist. Associated with Takeda. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — icatibant acetate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
icatibant acetate (ICATIBANT ACETATE) is a bradykinin b2 receptor antagonist. Associated with Takeda. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bradykinin B2 receptor antagonist
Primary target: B2 bradykinin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is icatibant acetate?
icatibant acetate (ICATIBANT ACETATE) is a bradykinin b2 receptor antagonist. Associated with Takeda. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for icatibant acetate?
ICATIBANT ACETATE is a marketed brand name for icatibant acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of icatibant acetate?
icatibant acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.